

<b>[T1] Therapeutic Antibodies and Beyond</b>	
April 9(Thur), 09:30~17:30 / Room.308	
Recently, new innovative approaches using therapeutic antibodies were suggested. This track will concentrate on antibody-drug conjugates, chimeric antigen receptor T-cell therapy, and technologies backing the development of therapeutic antibodies.	
<b>Session 1. Development of Antibody Drug Conjugates</b>	09:30~11:30
<p>Antibody-drug conjugates (ADCs) are the fastest growing market among the next generation of therapeutic antibodies. The global market for ADC drugs reached \$179 million in 2012 and \$396 million in 2013. The market is estimated to reach \$2.8 billion in 2018. Currently there are two FDA-approved ADCs in market; Brentuximab vedotin (trade name: Adcetris®, marketed by Seattle Genetics and Millennium/Takeda) and Trastuzumab emtansine (trade name: Kadcyla®, marketed by Genentech and Roche). More than 30 ADCs are currently in clinical trials. In this session, up-to-date ADC developments will be presented and discussed.</p>	
Session Chair	Byeong Doo Song, President, Scripps Korea Antibody Institute, Korea
Speakers	
09:30~10:10	<b>Antibody Drug Conjugate</b> <i>To be updated</i>
10:10~10:50	<b>Technology Platforms as a Business Model for BioTech Companies: The Case of Rottapharm Biotech</b> <i>Federica Girolami, Head of Department, Business Development and Scientific Liaison, Rottapharm Biotech, Italy</i>
10:50~11:30	<b>Development of New Complement C5 Neutralizing Antibody</b> <i>Dongjo Kim, Senior Manager, R&amp;D Divisional Group, Celltrion, Korea</i>
11:30~13:00	Session Break

<b>Session 2. Development of Chimeric Antigen Receptor T-cell Therapy</b>		13:00~15:00
<p>Recently Chimeric Antigen Receptor T-cell Therapy (CAR-T) has risen as a promising therapeutic tool for immunotherapy against cancer. CAR-T uses the patient's autologous effector T-cells, modifying it with a synthetic receptor and antibodies enabling it to increase the tumor specific immune response. This therapy is expected to first enter market with the launch of CTL019 by Novartis, which was provided with status of 'breakthrough therapy' by FDA, in the next few years. In recent trials, CTL019 has shown complete remission in children with advanced cases of treatment-resistant acute lymphoblastic leukemia (ALL). This session is focused on recent advances and developments of CAR-T.</p>		
Session Chair	Junho Chung, Professor, Department of Biochemistry and Molecular Biology, Seoul National University, Korea	
Speakers		
<b>13:00~13:40</b>	<b>T-cells and Tumor</b>	<i>Phillip Darcy, Associate Professor, Department of Oncology, Sir Peter MacCallum cancer centre, University of Melbourne, Australia</i>
<b>13:40~14:20</b>	<b>Current Trends of Chimeric Antigen Receptor (CAR) Therapy for Cancer</b>	<i>Sungyoo Cho, Senior Scientist, Mogam Biotechnology Institute, Green Cross, Korea</i>
<b>14:20~15:00</b>	<b>A Novel Platform Technology for Universal CAR-T Therapy</b>	<i>Junho Chung, Professor, Department of Biochemistry and Molecular Biology, Seoul National University, Korea</i>

<b>Session 3. Technology Development for the Development of Therapeutic Antibodies</b>		15:30~17:30
<p>Behind the rapid development of therapeutic antibodies, there was a huge advancement of biological technology. Every step of antibody development such as selecting lead antibodies with optimal characteristics, stably expressing antibodies and designing preclinical studies involve highly technological process. In this session these technologies will be reviewed and discussed in detail.</p>		
Session Chair	Park Youngwoo, Principal Investigator, Aging Intervention Research Center, Korea Research Institute of Bioscience & Biotechnology(KRIBB), Korea	
Speakers		
<b>15:30~16:10</b>	<b>Developability: Reducing the Risk of Failure of Biotherapeutics</b>	<i>Yvette Stallwood, Head, Applied Protein Sciences, Lonza Biologics plc, United Kingdom</i>
<b>16:10~16:50</b>	<b>Bioanalysis, ADME and PK/PD: Challenges and Strategies for ADC Development</b>	<i>YoungKun Shin, Professor, Department of Pharmacology, Chungnam National University, Korea</i>
<b>16:50~17:30</b>	<b>Panel Discussion</b>	<i>Koonmin Lee, Professor, Department of Biological Sciences, Korea Advanced Institute of Science and Technology(KAIST), Korea JongWon Kim, Principal investigator, Division of Drug Screening and Evaluation, Csong New Drug Development Center, Korea</i>